CN104379215B - 雷帕霉素组合物 - Google Patents

雷帕霉素组合物 Download PDF

Info

Publication number
CN104379215B
CN104379215B CN201280061480.1A CN201280061480A CN104379215B CN 104379215 B CN104379215 B CN 104379215B CN 201280061480 A CN201280061480 A CN 201280061480A CN 104379215 B CN104379215 B CN 104379215B
Authority
CN
China
Prior art keywords
polyethylene oxide
block copolymer
pluronic
hydrophobic
average molecular
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201280061480.1A
Other languages
English (en)
Chinese (zh)
Other versions
CN104379215A (zh
Inventor
格莱泽格尔兹·皮尔特泽恩斯基
瓦莱利·阿拉克霍夫
基肖·帕特伊
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
TARTIS AGING Inc
Original Assignee
TARTIS AGING Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by TARTIS AGING Inc filed Critical TARTIS AGING Inc
Publication of CN104379215A publication Critical patent/CN104379215A/zh
Application granted granted Critical
Publication of CN104379215B publication Critical patent/CN104379215B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Processes Of Treating Macromolecular Substances (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
CN201280061480.1A 2011-12-13 2012-12-13 雷帕霉素组合物 Expired - Fee Related CN104379215B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13/324,407 US8912215B2 (en) 2011-12-13 2011-12-13 Rapamycin composition
US13/324,407 2011-12-13
PCT/US2012/069544 WO2013090602A2 (en) 2011-12-13 2012-12-13 Rapamycin composition

Publications (2)

Publication Number Publication Date
CN104379215A CN104379215A (zh) 2015-02-25
CN104379215B true CN104379215B (zh) 2017-08-04

Family

ID=48572556

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201280061480.1A Expired - Fee Related CN104379215B (zh) 2011-12-13 2012-12-13 雷帕霉素组合物

Country Status (8)

Country Link
US (1) US8912215B2 (enExample)
EP (1) EP2790700B1 (enExample)
JP (1) JP6077001B2 (enExample)
CN (1) CN104379215B (enExample)
GE (1) GEP201706651B (enExample)
RU (1) RU2557919C1 (enExample)
UA (1) UA115137C2 (enExample)
WO (1) WO2013090602A2 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP1400075A2 (hu) * 2014-02-14 2015-08-28 Druggability Technologies Ip Holdco Jersey Ltd Sirolimus és származékainak komplexei, elõállítása és gyógyszerészeti kompozíciói
CN105794803B (zh) * 2016-05-06 2018-06-05 重庆大学 Tor蛋白抑制剂抑制植物枯萎病菌、黄萎病菌的新用途
CN105918330B (zh) * 2016-05-24 2018-06-05 重庆大学 雷帕霉素抑制植物早疫病菌的新用途
CN112137961A (zh) * 2020-09-30 2020-12-29 严鹏科 一种雷帕霉素组合物及其制备方法
WO2023145867A1 (ja) * 2022-01-31 2023-08-03 住友精化株式会社 製剤用ポリアルキレンオキシド粒子、医薬用組成物、製剤用組成物及び製剤

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6387406B1 (en) * 1992-10-08 2002-05-14 Supratek Pharma Inc. Copolymer compositions for oral delivery

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA924953B (en) 1991-07-25 1993-04-28 Univ Louisville Res Found Method of treating ocular inflammation
US5840319A (en) 1992-10-08 1998-11-24 Alakhov; Valery Yu Biological agent compositions
US7205279B2 (en) * 1995-10-25 2007-04-17 Novartis Ag Pharmaceutical compositions
FR2736550B1 (fr) * 1995-07-14 1998-07-24 Sandoz Sa Composition pharmaceutique sous la forme d'une dispersion solide comprenant un macrolide et un vehicule
US6060518A (en) 1996-08-16 2000-05-09 Supratek Pharma Inc. Polymer compositions for chemotherapy and methods of treatment using the same
CA2230748C (en) * 1997-03-14 2010-08-03 American Home Products Corporation Rapamycin formulations for oral administration
US8257725B2 (en) 1997-09-26 2012-09-04 Abbott Laboratories Delivery of highly lipophilic agents via medical devices
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US7256180B2 (en) 2000-04-28 2007-08-14 Supratek Pharma Inc. Compositions and methods for inducing activation of dendritic cells
US20030054042A1 (en) * 2001-09-14 2003-03-20 Elaine Liversidge Stabilization of chemical compounds using nanoparticulate formulations
AU2003272471B2 (en) 2002-09-18 2010-10-07 Trustees Of The University Of Pennsylvania Method of inhibiting choroidal neovascularization
US9216106B2 (en) 2003-04-09 2015-12-22 Directcontact Llc Device and method for the delivery of drugs for the treatment of posterior segment disease
US7083802B2 (en) 2003-07-31 2006-08-01 Advanced Ocular Systems Limited Treatment of ocular disease
CA2539324A1 (en) 2003-09-18 2005-03-31 Macusight, Inc. Transscleral delivery
US20070059336A1 (en) 2004-04-30 2007-03-15 Allergan, Inc. Anti-angiogenic sustained release intraocular implants and related methods
US8663639B2 (en) 2005-02-09 2014-03-04 Santen Pharmaceutical Co., Ltd. Formulations for treating ocular diseases and conditions
WO2006094507A1 (en) 2005-03-08 2006-09-14 Lifecycle Pharma A/S Pharmaceutical compositions comprising sirolimus and/or an analogue thereof
AU2006227116A1 (en) 2005-03-21 2006-09-28 Santen Pharmaceutical Co., Ltd. Drug delivery systems for treatment of diseases or conditions
US20060247265A1 (en) 2005-04-28 2006-11-02 Clackson Timothy P Therapies for treating disorders of the eye
US20090053391A1 (en) 2005-12-06 2009-02-26 Ludwig Florian N Method Of Coating A Drug-Releasing Layer Onto A Substrate
CN101605529B (zh) 2006-02-09 2013-03-13 参天制药株式会社 稳定制剂及它们的制备和使用方法
US8148338B2 (en) * 2006-02-22 2012-04-03 Supratek Pharma Inc. Doxorubicin formulations for anti-cancer use
BRPI0709016A2 (pt) 2006-03-23 2011-06-21 Macusight Inc formulações e métodos para doenças ou condições relacionadas com a permeabilidade vascular
RU2010104916A (ru) 2006-08-16 2011-08-20 Михаил В. Благосклонный (US) Способ профилактики и лечения возрастных заболеваний
GB0625844D0 (en) 2006-12-22 2007-02-07 Daniolabs Ltd The treatment of macular degeneration
US11078262B2 (en) 2007-04-30 2021-08-03 Allergan, Inc. High viscosity macromolecular compositions for treating ocular conditions
US20110014117A1 (en) 2007-06-28 2011-01-20 Schering Corporation Anti-igf1r
US20090035381A1 (en) 2007-08-01 2009-02-05 Stankus John J Electrospraying method for fabrication of particles and coatings and treatment methods thereof
CN101827523A (zh) 2007-08-16 2010-09-08 马库赛特公司 用于治疗眼部疾病或病症的制剂
ES2667945T3 (es) 2007-10-08 2018-05-16 Aurinia Pharmaceuticals Inc. Composiciones oftálmicas que comprenden inhibidores de calcineurina o Inhibidores de mTOR
EP2197428B1 (en) 2007-10-16 2012-01-25 Pharmathen S.A. Improved pharmaceutical composition containing a pyrrolidone anticonvulsant agent and method for the preparation thereof
WO2009073843A1 (en) 2007-12-06 2009-06-11 Cytotech Labs, Llc Inhalable compositions having enhanced bioavailability
US20090291073A1 (en) 2008-05-20 2009-11-26 Ward Keith W Compositions Comprising PKC-theta and Methods for Treating or Controlling Ophthalmic Disorders Using Same
US20100040669A1 (en) 2008-08-12 2010-02-18 Higuchi John W Non-Invasive Ocular Delivery of Rapamycin
EP2427174A4 (en) 2009-05-04 2014-01-15 Santen Pharmaceutical Co Ltd HEMMER OF THE MTOR SIGNAL PATH FOR THE TREATMENT OF EYE TROUBLE
CA2665956A1 (en) 2009-05-07 2010-11-07 Samir Patel Combination treatment for ocular diseases
US9101541B2 (en) * 2010-04-28 2015-08-11 Cadila Healthcare Limited Stable solid pharmaceutical matrix compositions of sirolimus

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6387406B1 (en) * 1992-10-08 2002-05-14 Supratek Pharma Inc. Copolymer compositions for oral delivery

Also Published As

Publication number Publication date
EP2790700A4 (en) 2015-10-14
EP2790700A2 (en) 2014-10-22
WO2013090602A3 (en) 2014-12-24
US8912215B2 (en) 2014-12-16
US20130150397A1 (en) 2013-06-13
CN104379215A (zh) 2015-02-25
JP6077001B2 (ja) 2017-02-08
RU2557919C1 (ru) 2015-07-27
JP2015513311A (ja) 2015-05-07
EP2790700B1 (en) 2017-10-25
WO2013090602A2 (en) 2013-06-20
UA115137C2 (uk) 2017-09-25
GEP201706651B (en) 2017-04-10

Similar Documents

Publication Publication Date Title
CN102215874B (zh) 活性剂的聚合物递送系统
CN103998037B (zh) 对高熔点疏水性化合物具有改进的生物利用度的药物组合物
US20200261583A1 (en) Thermogel formulation for combination drug delivery
KR101688038B1 (ko) 벤다무스틴의 경구 투약 형태
CN104379215B (zh) 雷帕霉素组合物
CA2640997C (en) Doxorubicin formulations for anti-cancer use
NL2023661B1 (en) Pharmaceutical Eutectic Salt Formulation
US8945627B2 (en) Micelles for the solubilization of gossypol
CN105232459A (zh) 一种复溶自组装的水难溶性药物聚合物胶束组合物及其制备方法
US20130296280A1 (en) Eutectic mixture comprising celecoxib and poloxamer
KR20130086157A (ko) 벤다무스틴의 경구 투약 형태
CN104173283B (zh) 一种以苯甲酰胺为基本骨架的Hsp90抑制剂的纳米混悬剂及其制备方法
Elshafeey et al. Sucrose acetate isobutyrate based nanovesicles: A promising platform for drug delivery and bioavailability enhancement
CN103179953A (zh) 含6’-氟-(n-甲基-或n,n-二甲基-)-4-苯基-4’,9’-二氢-3’h-螺[环己烷-1,1’-吡喃并[3,4,b]吲哚]-4-胺的药物剂型
US20130150311A1 (en) Mixed poloxamer excipients
WO2016008401A1 (zh) 一种含多西他赛的药物组合物
CN115969781A (zh) 一种枸橼酸爱地那非注射剂及其制备方法和用途
EP2240161A1 (en) Enhanced delivery of antifungal agents
CN103228280B (zh) 包含瑞伐拉赞或其盐的可注射液体组合物
US20090291132A1 (en) Enhanced delivery of antifungal agents
JP2011511059A (ja) 経口懸濁液用免疫抑制性マクロライド粉末
Alwiswasi et al. Ophthalmic Single and Mixed Polymeric Nanomicelles using Brimonidine as a model drug: Preparation, Characterization, and Physical Properties Evaluation
KR100299942B1 (ko) 비페닐디메칠디카르복실레이트의액제
WO2017046037A1 (en) Nanoparticles loaded with active ingredients, their process of preparation and their uses
EP3220954A2 (en) Process for preparation of parenteral formulation of anidulafungin

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20170804

Termination date: 20201213